Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors

NCT01831089 is registered in ClinicalTrials.gov with PharmaMar as lead sponsor.

NCT NCT01831089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01831089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors
Lead sponsor
PharmaMar
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2013
Completion date
July 31, 2016
Enrollment
69 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, gynecological cancer, head and neck carcinoma, non-small cell lung cancer, non-squamous cell lung cancer, ovarian cancer, small cell lung cancer